AMRN - Amarin Corporation plc Stock Trading

Intercept Pharmaceuticals (NASDAQ: ICPT)  is in the enviable position of many biotech companies. It boasts a marketed drug on pace to deliver more than $200 million in sales for 2019 and is anticipating an upcoming decision from the Food and Drug Administration that could grant it the fi...

Generally speaking, biotech stocks were one of the best places to put your money in 2019. The iShares Nasdaq Biotechnology ETF gained a stellar 25.2% last year, despite the political wrangling over prescription drug prices in the United States. Fortunately, this upward trend should continue un...

Amarin (NASDAQ: AMRN) is about to make a boatload of money. Probably no one familiar with the biotech would argue that point. In December, the FDA gave the go-ahead to a new label expansion for Amarin's sole approved drug, Vascepa, in reducing cardiovascular risk. While Vascepa has been o...